Literature DB >> 23110409

Clinical and economic burden of community-acquired pneumonia in the Medicare fee-for-service population.

Holly Yu1, Jaime Rubin, Stephan Dunning, Suying Li, Reiko Sato.   

Abstract

OBJECTIVES: To estimate current community-acquired pneumonia (CAP) incidence and its associated economic burden in the Medicare fee-for-service (FFS) population.
DESIGN: Retrospective.
SETTING: The 2007/08 Medicare Standard Analytic Files, a nationally representative random sample (5%) of Medicare beneficiaries enrolled in the FFS program. PARTICIPANTS: Residents of one of the 50 U.S. states or the District of Columbia aged 18 and older on July 1, 2007, with continuous Part A and Part B coverage during calendar year 2007. MEASUREMENTS: Incidence, episode length, mortality, and costs were assessed. All-cause costs were assessed using three methodologies: costs during the episode, and incremental costs using CAP cases as self-control (before-after) and with matched controls (case-control).
RESULTS: Sixty-five thousand eight hundred four CAP episodes (39% inpatient-treated episodes) were identified. Average inpatient and outpatient episode lengths were 32.8 ± 46.9 and 12.4 ± 27.3 days, respectively, and overall incidence was 4,482/100,000 person-years. Thirty-day case fatality was 8.5% for inpatient and 3.8% for outpatient CAP. The average CAP episode cost was $8,606 ($18,670 for inpatient, $2,394 for outpatient). The incremental cost of a CAP episode in the before-and-after and case-control analyses was approximately $10,000.
CONCLUSION: An estimated 1.3 million CAP cases and 74,000 CAP-related deaths were found, with an economic burden of $13 billion annually in the Medicare fee-for-service population. Preventing CAP in this population may substantially reduce healthcare costs.
© 2012, Copyright the Authors Journal compilation © 2012, The American Geriatrics Society.

Entities:  

Mesh:

Year:  2012        PMID: 23110409     DOI: 10.1111/j.1532-5415.2012.04208.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  33 in total

Review 1.  Pneumococcal vaccine and patients with pulmonary diseases.

Authors:  Mehdi Mirsaeidi; Golnaz Ebrahimi; Mary Beth Allen; Stefano Aliberti
Journal:  Am J Med       Date:  2014-05-20       Impact factor: 4.965

2.  Risk factors for pulmonary embolism in patients preliminarily diagnosed with community-acquired pneumonia: a prospective cohort study.

Authors:  Yunfeng Zhang; Qixing Zhou; Ying Zou; Xiaolian Song; Shuanshuan Xie; Min Tan; Guoliang Zhang; Changhui Wang
Journal:  J Thromb Thrombolysis       Date:  2016-05       Impact factor: 2.300

3.  Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemics.

Authors:  Mohamed A Kamal; Patrick F Smith; Nathorn Chaiyakunapruk; David B C Wu; Chayanin Pratoomsoot; Kenneth K C Lee; Huey Yi Chong; Richard E Nelson; Keith Nieforth; Georgina Dall; Stephen Toovey; David C M Kong; Aaron Kamauu; Carl M Kirkpatrick; Craig R Rayner
Journal:  Br J Clin Pharmacol       Date:  2017-02-20       Impact factor: 4.335

4.  Effects of utilization management on health outcomes: evidence from urinary tract infections and community-acquired pneumonia.

Authors:  Martin Andersen; Anurag Pant
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2022-04-27       Impact factor: 2.039

5.  The incidence rate and economic burden of community-acquired pneumonia in a working-age population.

Authors:  Jonah Broulette; Holly Yu; Bruce Pyenson; Kosuke Iwasaki; Reiko Sato
Journal:  Am Health Drug Benefits       Date:  2013-09

6.  Pneumococcal vaccines: understanding centers for disease control and prevention recommendations.

Authors:  Mehdi Mirsaeidi; Dean E Schraufnagel
Journal:  Ann Am Thorac Soc       Date:  2014-07

Review 7.  Integrative Physiology of Pneumonia.

Authors:  Lee J Quinton; Allan J Walkey; Joseph P Mizgerd
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

8.  Cost-utility analysis of antiviral use under pandemic influenza using a novel approach - linking pharmacology, epidemiology and heath economics.

Authors:  D B C Wu; N Chaiyakunapruk; C Pratoomsoot; K K C Lee; H Y Chong; R E Nelson; P F Smith; C M Kirkpatrick; M A Kamal; K Nieforth; G Dall; S Toovey; D C M Kong; A Kamauu; C R Rayner
Journal:  Epidemiol Infect       Date:  2018-02-15       Impact factor: 4.434

9.  Community-acquired pneumonia episode costs by age and risk in commercially insured US adults aged ≥50 years.

Authors:  Reiko Sato; Gabriel Gomez Rey; Stephanie Nelson; Brett Pinsky
Journal:  Appl Health Econ Health Policy       Date:  2013-06       Impact factor: 2.561

10.  Efficacy of Omadacycline Versus Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia by Disease Severity: Results From the OPTIC Study.

Authors:  Julio Ramirez; Daniel H Deck; Paul B Eckburg; Marla Curran; Anita F Das; Courtney Kirsch; Amy Manley; Evan Tzanis; Paul C McGovern
Journal:  Open Forum Infect Dis       Date:  2021-06-18       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.